Αρχειοθήκη ιστολογίου

Δευτέρα 2 Οκτωβρίου 2017

Trastuzumab Biosimilar on Track for Approval [News in Brief]

An FDA expert panel recommended approval of Mylan's MYL-14010, a biosimilar candidate for Genentech's trastuzumab, putting it on track to become the first approved biosimilar for cancer. Experts predict that biosimilars will lead to lower drug prices, but caution that the savings won't be as dramatic as that seen with generics.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2wtYlaR

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου